Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Recruiting · NCT07361705 · Registry updated 2026-06-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression | Neoplasms by Site, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges | Recruiting | Phase 1 | 2026-06-22 | NCT07361705 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alpha Biopharma (Jiangsu) Co., Ltd. | 3 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 71 |
| Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital | Guangzhou | China | 1 |
| Henan Cancer Hospital | Henan | China | 1 |
| Shanxi Cancer Hospital | Shanxi | China | 1 |
| The First Affiliated Hospital of China Medical University | Shengyang | China | 1 |